Could Investment Portfolio Ameliorate the Investment Risk and Return Under Covid-19 in the US Pharmaceuticals Industry?
These authors contributed equally.
- DOI
- 10.2991/aebmr.k.220307.413How to use a DOI?
- Keywords
- portfolio; investment; mean-variance; Sharpe ratio; treasury bill
- Abstract
To relieve the huge blow to the economy caused by the COVID-19 pandemic, this article is to verify that investment portfolio is an efficient method when investing in the US pharmaceuticals industry by utilizing daily stock prices of 4 out of the top 10 US pharmaceutical companies and treasury bill during the last 2 years (Aug 2019 to Aug 2021). We obtained the monthly rate of return and applied mean-variance strategies to individual companies and portfolios. We drew CAPM and efficient frontier and used the Sharpe ratio as a measurement to test portfolio efficiency. The empirical results are given 3 special portfolios: minimum variance, maximum expected return and maximum Sharpe ratio. The highest Sharpe ratio in portfolios is higher than all single stocks. Portfolios with treasury bills have a higher return, higher risk, and similar Sharpe ratio with portfolios without risk-free rate as treasury bills also experienced a huge shock during the pandemic. According to these results, we can conclude that investment portfolios do help investors alleviate the impact of COVID-19 on the economy and get better returns in the economic downturn.
- Copyright
- © 2022 The Authors. Published by Atlantis Press International B.V.
- Open Access
- This is an open access article under the CC BY-NC license.
Cite this article
TY - CONF AU - Fuqing He AU - Haojin Liang AU - Ziyao Yuan PY - 2022 DA - 2022/03/26 TI - Could Investment Portfolio Ameliorate the Investment Risk and Return Under Covid-19 in the US Pharmaceuticals Industry? BT - Proceedings of the 2022 7th International Conference on Financial Innovation and Economic Development (ICFIED 2022) PB - Atlantis Press SP - 2526 EP - 2536 SN - 2352-5428 UR - https://doi.org/10.2991/aebmr.k.220307.413 DO - 10.2991/aebmr.k.220307.413 ID - He2022 ER -